The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes

Monday, October 12, 2026 edition, released Tuesday, October 13, 2026. News checked through October 13, 2026; no material updates to the stories below were found.Bristol's admilparant met its Phase 3 lung-function endpoint at the lower dose, while the higher dose missed significance in idiopathic pulmonary fibrosis. Its acquired RYZ101 program also delivered a Phase 3 win in neuroendocrine tumors after lutetium therapy, with benefit size still undisclosed. Mirum's LIVMARLI (maralixibat) reduced childhood itch in EXPAND, while the roundup covers First Tracks' ANB033 in celiac disease, Sebela's tegoprazan in reflux, Zenas' obexelimab in IgG4-related disease, Claris' eye-drop data and Ascelia's Orviglance regulatory path.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

Merck's remigromig met BRUNELLO's noninferiority bar in diabetic macular edema, but showed no superiority and a notable safety imbalance. AstraZeneca completed its $2 billion Summit Therapeutics investment around ivonescimab combinations, while Roche's vamikibart entered FDA review with mixed Phase 3 evidence behind the filing. The Sunday, October 11 Week in Review—released Monday, October 12—also spans oncology, cardiometabolic and rare disease, respiratory and neuroscience, immunology, vaccines, infectious disease, access and medicine safety. Across 45 news stories and three forward watches, Alex and Maya separate completed events and clinical results from filings, plans and pending catalysts.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

The Pharma Closeout's MDS 2026 Debrief covers the readouts from the International Parkinson and Movement Disorder Society congress in Seoul that matter for drug, diagnostic and payer strategy. Biogen and Denali'sLUMA and Bial's ACTIVATE showed full data on two genetic bets in Parkinson's disease that missed, and we look at what still stands: Arvinas's LRRK2 degrader, a spinal-fluid marker that could help pick patients, and Roche's prasinezumab Phase 3. AbbVie's newly approved Juvmo meets ICER's numbers, and we put Cerevance's solengepras result against the approved add-ons. Plus Syntara's trial in REM sleep behaviour disorder, a skin test for alpha-synuclein, Praxis's essential tremor drug, Teva's ecopipam in Tourettesyndrome, Neurocrine's five-year valbenazine data, and what to watch: the Huntington's congress, ICER's final report, Austedo's Medicare price and Praxis's FDA date.0:00 Cold open and introduction1:02 Story of the Congress: two genetic bets fall in full data4:03 The remaining bets: Arvinas's degrader, a spinal-fluid marker, Roche's prasinezumab6:00 AbbVie's Juvmo meets ICER8:11 Solengepras: how to read 37 minutes9:48 Before diagnosis: Syntara's REM sleep trial and a skin test11:48 Beyond Parkinson's: essential tremor, Tourette syndrome, Huntington's disease14:15 What to watch: Huntington's congress, ICER's final report, Austedopricing, Praxis's FDA dateAlex Mercer and Maya Patel host. Get the daily rundown inyour inbox — subscribe at https://thepharmacloseout.com.

Friday, October 9 edition, released late Saturday, October 10.FDA approved Hovilpri (pritelivir) for immunocompromised adults with stubborn herpes simplex lesions, but the oral drug is not yet available and is expected in the U.S. before the end of 2026. Biohaven agreed to license rights for parts of Asia to Phase 3 Graves' disease candidate BHV-1300 to Ono for $80 million at closing, plus a separate conditional $20 million; the deal is not evidence of efficacy. Also: J&J reports two-year Icotyde PASI 90 results without a long-term Sotyktu comparison, and Pennsylvania details GSK's $800 million-plus Upper Merion manufacturing expansion.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

Thursday, October 8 edition, published after midnight Pacific.FDA approves Roche's Tecentriq (atezolizumab) with chemotherapy after stage III dMMR colon cancer surgery: fewer recurrence-or-death events, more frequent grade 3–4 adverse events. Bristol Myers Squibb reports a topline median progression-free survival of 42 vs 20 months for Zenbexus (iberdomide) in multiple myeloma; the result is not peer-reviewed, reports no overall survival result, and whether it verifies clinical benefit is the FDA's call. argenx stops its Phase 3 UNITY study of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase) in Sjögren's disease and says FB102 met its Phase 2 celiac primary endpoint. Plus Viatris's pending $1.65 billion Pacira deal (EXPAREL, ZILRETTA), PhRMA's GLOBE lawsuit, GenSight's GS030 retinitis pigmentosa study and Valneva's UK IXCHIQ revocation.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.